Sourcing Quality Boswellia
How to judge Boswellia extract quality, AKBA standardisation, and formulation relevance for oncology-oriented use
For oncology-oriented use, generic Boswellia or frankincense products without meaningful AKBA standardisation are usually not enough.
What to look for
a product that states AKBA content clearly
total boswellic acids are clearly stated
no unnecessary fillers
confidence about the extract quality and testing
practical ability to reach research-relevant daily intake
Why AKBA matters
Many Boswellia products advertise only total boswellic acids, but the strongest oncology literature focuses specifically on AKBA.
That means a product can look strong on paper but still be weak for oncology-oriented use if it does not provide meaningful AKBA.
Practical buying logic
When comparing Boswellia products, ask:
How much AKBA does this provide?
How much total extract is required to reach useful levels?
Does the product make it practical to dose throughout the day?
Is the extract likely to be better absorbed with food?
Practical takeaway
For oncology-oriented discussion, AKBA-standardised Boswellia is more relevant than a generic frankincense or resin-support product.
Group-trusted Boswellia options
At the moment, two MCS options are particularly relevant for readers seeking to align more closely with the AKBA-focused oncology literature.
Option 1 — Boswellia MEGA AKBA Liposomal
200 mg Boswellia serrata extract per capsule
30% AKBA
60 mg AKBA per capsule
60 capsules
€37.60
contains piperlongumine
This is the more accessible liposomal option and appears to be designed to improve absorption while still providing meaningful AKBA exposure.
Using the currently supplied product details:
4 capsules per day would provide about 240 mg AKBA daily
That is a practical way to approximate the lower end of more treatment-oriented AKBA exposure
Option 2 — Inflasanum 200mg
practitioner-script product
has as a higher-90% AKBA per 200mg Boswellia option
providing 180 mg AKBA per capsule
60 capsules per box
€82.72
does not contain piperlongumine
This is the more concentrated option and may be the better fit for readers who want:
fewer capsules per day
No piperlongumine in the formula
a more clinician-supervised approach
Important note: the product details supplied for Inflasanum include differing AKBA figures. Before using it for protocol-style dosing, readers should confirm the current label or product sheet directly so daily AKBA calculations are based on the exact active amount in the current version.
What the difference means in practice
Boswellia MEGA AKBA Liposomal
Best for readers who want:
a liposomal delivery format
a lower-cost entry point
a product that already includes a bioavailability-support strategy
no script required
Inflasanum
Best for readers who want:
a higher-strength, fewer-capsule approach
a piperlongumine-free option
a product more suited to supervised use, where the clinician is comfortable reviewing the full interaction picture
Support in getting the written 'Inflasanum' request below:
You can copy this short note for a practitioner‑only Boswellia product (Inflasanum 200 mg) without Piperlongumine; the target daily AKBA dose is based on published brain/radiation‑edema data.
In the email sent to oncologist you could write:
"I’d be grateful if you could review and sign it if you feel it is safe alongside my current treatments"
Before giving the oncologist fill in your personal details:
Patient: [Full name, DOB]
Diagnosis: [ --— ]I support the use of a high‑AKBA Boswellia serrata supplement as an adjunct to help manage [e.g radiation‑related inflammation and edema in the skull/bone, alongside current standard oncologic care].
Product requested: Inflasanum 200 mg (high‑AKBA Boswellia serrata), piperlongumine‑free.
Target AKBA dosing consistent with brain/radiation edema research: approximately 540 mg AKBA per day, in divided doses, subject to tolerance.
Based on the current product information supplied (≈180 mg AKBA per capsule), this corresponds to:
– 1 capsule three times daily 20 min before food.Please supply:
– Inflasanum 200 mg, 60 capsules
– Dose: 1 capsule, 3 times daily, with or shortly before food, as tolerated.
– Intended duration: up to 3 months before review.I am aware this is a Boswellia serrata extract and will monitor for gastrointestinal side‑effects, hepatic function, and any interaction concerns with her chemotherapy regimen.
Signed:
Name:
Title / Specialty:
Date:
Why the piperlongumine difference matters
Piperlongumine may improve the absorption of boswellic acids, which could be beneficial. But during active treatment, some readers may reasonably prefer a formula without it if there are concerns that extra absorption-enhancing effects could also alter concurrent drug and supplement tolerance or side-effect burden.
That does not mean piperlongumine is inappropriate. It means the choice between these two formulas may depend in part on how simple and conservative a patient wants the treatment-support stack to be during active therapy.
Practical buying logic
The main questions are not just price or capsule count. They are:
How much actual AKBA does the product provide?
Is the formula designed to improve absorption?
Does it contain anything else, such as piperlongumine, that may change the clinical discussion?
Is the product realistic to dose at research-oriented levels without excessive capsule burden?
Community discussions
Read about how other group members source and use high quality Boswellia with standardised high dose AKBA content. This image is located in the study support group's media library and is the anchor to the constant conversation thread on this topic: Group discussion thread
Cancer Patient Community Most Trusted Products
Boswellia MEGA AKBA Liposomal
https://www.mcsformulas.com/vitamins-supplements/boswellia-akba-liposomal/ref/14
Inflasanum
https://www.mcsformulas.com/vitamins-supplements/inflasanum-180mg/ref/14
Use the code abbey5 at checkout to save 5% and help support the free Healing Cancer Study Support resources.
Important caution
This comparison is a practical interpretation of current product information, not a dosing prescription.
Formulation, food timing, absorption, treatment type, and drug interactions all matter. Boswellia still deserves the same interaction review as any active adjunct, especially in people using anticoagulants, corticosteroids, endocrine therapy, taxanes, or other CYP-relevant drugs.
Jump to another Boswellia page
Core pages
Mechanism deep dives
Practical pages
Cancer-type pages
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.